Get the Stockscreener App
1.64
0.61%
0.01
After Hours:
1.64
Invivyd Inc stock is traded at $1.64, with a volume of 6.86M.
It is up +0.61% in the last 24 hours and up +41.38% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.63
Open:
$1.63
24h Volume:
6.86M
Relative Volume:
1.23
Market Cap:
$197.03M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.8367
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
+34.43%
1M Performance:
+41.38%
6M Performance:
+230.11%
1Y Performance:
+80.92%
1-Day Range:
$1.60
$1.785
1-Week Range:
$1.145
$1.785
52-Week Range:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.64 | 349.49M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Are Investors Undervaluing Invivyd, Inc. (NASDAQ:IVVD) By 31%? - 富途牛牛
Invivyd (IVVD) Is Up 26.8% After FDA Clears Phase 3 Trials for COVID Antibody Candidate - simplywall.st
Invivyd (IVVD): Assessing Valuation After FDA Clears Phase 3 COVID-19 Antibody Trial - Yahoo Finance
D. Boral Capital Maintains Invivyd (IVVD) Buy Recommendation - Nasdaq
Invivyd receives FDA clearance for COVID antibody prevention trials By Investing.com - Investing.com Nigeria
D. Boral Capital Increases Invivyd (NASDAQ:IVVD) Price Target to $2.00 - MarketBeat
Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program - MarketScreener
New Haven biotech advances vaccine-alternative to prevent COVID - Hartford Business Journal
Invivyd stock soars after FDA clears IND for COVID antibody candidate - Investing.com
Cantor Fitzgerald Initiates Invivyd at Overweight With $10 Price Target - MarketScreener
This Commerce Bancshares Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug - MarketScreener
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Invivyd (NASDAQ:IVVD) Now Covered by Cantor Fitzgerald - MarketBeat
Invivyd announces IND clearance, alignment with FDA on VYD2311 program - TipRanks
Invivyd’s VYD2311 Receives FDA Clearance for Trials - TipRanks
Invivyd receives FDA clearance for COVID antibody prevention trials - Investing.com
Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311 - MarketScreener
Invivyd Announces Upcoming Phase 3 Clinical Trials for VYD2311, a Novel COVID Prevention Therapy - Quiver Quantitative
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - Yahoo Finance
How supply chain issues affect Invivyd Inc. stockWeekly Gains Summary & High Conviction Trade Alerts - newser.com
Is Invivyd Inc. stock in correction or buying zone2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
What to do if you’re stuck in Invivyd Inc.Exit Point & Fast Exit and Entry Trade Guides - newser.com
Earnings visualization tools for Invivyd Inc.July 2025 Intraday Action & Daily Profit Focused Screening - newser.com
How Invivyd Inc. stock performs in interest rate cyclesGap Down & Weekly Return Optimization Plans - newser.com
Why retail investors pile into Invivyd Inc. stockJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
How moving averages guide Invivyd Inc. tradingPortfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com
Multi asset correlation models including Invivyd Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Is Invivyd Inc. stock safe for conservative investorsWeekly Investment Report & Fast Momentum Entry Tips - newser.com
Applying chart zones and confluence areas to Invivyd Inc.2025 Investor Takeaways & Long-Term Safe Investment Plans - newser.com
Can you recover from losses in Invivyd Inc.2025 Winners & Losers & Growth Focused Stock Pick Reports - newser.com
Is Invivyd Inc a good long term investmentVolume Analysis Techniques & Free Double Digit Growth Tips - earlytimes.in
What analysts say about Invivyd Inc stockStock Rotation Strategies & Small Budget Trading Ideas - earlytimes.in
Invivyd Appoints New Director Amid Nasdaq Compliance - The Globe and Mail
Invivyd appoints Wave Life Sciences CEO to board of directors By Investing.com - Investing.com Australia
Invivyd appoints Wave Life Sciences CEO to board of directors - Investing.com
Invivyd Appoints Paul B. Bolno, M.D. To Its Board Of Directors - TradingView
Invivyd, Inc. Appoints Dr. Paul B. Bolno to Board of Directors - Quiver Quantitative
Invivyd appoints Wave Life Sciences CEO Paul Bolno to board - TipRanks
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors - The Manila Times
How to contact the Daily Bulletin - FinancialContent
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
88,987 |
| Duke William E. | Chief Financial Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Duke William E. | Chief Financial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Green Julie | Chief Human Resources Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Green Julie | Chief Human Resources Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 19 '25 |
Sale |
0.57 |
49,402 |
27,991 |
84,446 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 18 '25 |
Sale |
0.65 |
33,352 |
21,685 |
133,848 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 19 '25 |
Sale |
0.57 |
27,420 |
15,536 |
53,068 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 18 '25 |
Sale |
0.65 |
18,512 |
12,037 |
80,488 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):